» Articles » PMID: 15756023

Growth Inhibition of Multiple Myeloma Cells by a Novel IkappaB Kinase Inhibitor

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2005 Mar 10
PMID 15756023
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Involvement of nuclear factor-kappaB (NF-kappaB) in cell survival and proliferation of multiple myeloma has been well established. In this study we observed that NF-kappaB is constitutively activated in all human myeloma cell lines, thus confirming the previous studies. In addition, we found the phosphorylation of p65 subunit of NF-kappaB in addition to the phosphorylation of IkappaBalpha and the activation of NF-kappaB DNA binding and that various target genes of NF-kappaB including bcl-x(L), XIAP, c-IAP1, cyclin D1, and IL-6 are up-regulated. We then examined the effect of a novel IkappaB kinase inhibitor, 2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-yl nicotinonitrile (ACHP). When myeloma cells were treated with ACHP, the cell growth was efficiently inhibited with IC(50) values ranging from 18 to 35 mumol/L concomitantly with inhibition of the phosphorylation of IkappaBalpha/p65 and NF-kappaB DNA-binding, down-regulation of the NF-kappaB target genes, and induction of apoptosis. In addition, we observed the treatment of ACHP augmented the cytotoxic effects of vincristine and melphalan (l-phenylalanine mustard), conventional antimyeloma drugs. These findings indicate that IkappaB kinase inhibitors such as ACHP can sensitize myeloma cells to the cytotoxic effects of chemotherapeutic agents by blocking the antiapoptotic nature of myeloma cells endowed by the constitutive activation of NF-kappaB.

Citing Articles

CCR2 cooperativity promotes hematopoietic stem cell homing to the bone marrow.

Hurwitz S, Kobulsky D, Jung S, Chia J, Butler J, Kurre P Sci Adv. 2024; 10(38):eadq1476.

PMID: 39292787 PMC: 11409967. DOI: 10.1126/sciadv.adq1476.


Induced dual-target rebalance simultaneously enhances efficient therapeutical efficacy in tumors.

Zhang X, Ding T, Yang F, Xu H, Zhang J, Bai Y Cell Death Discov. 2024; 10(1):249.

PMID: 38782895 PMC: 11116470. DOI: 10.1038/s41420-024-02018-y.


A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.

Gao J, Zhou J, Zhang M, Zhang Y, Zeng Y, Li S Mol Cell Biochem. 2023; 479(4):843-857.

PMID: 37204666 DOI: 10.1007/s11010-023-04764-6.


Antioxidant and Anti-Inflammatory Effects of Thyme ( L.) Essential Oils Prepared at Different Plant Phenophases on LPS-Activated THP-1 Macrophages.

Pandur E, Micalizzi G, Mondello L, Horvath A, Sipos K, Horvath G Antioxidants (Basel). 2022; 11(7).

PMID: 35883820 PMC: 9311800. DOI: 10.3390/antiox11071330.


Advances in Immunosuppressive Agents Based on Signal Pathway.

Xu Z, Chu M Front Pharmacol. 2022; 13:917162.

PMID: 35694243 PMC: 9178660. DOI: 10.3389/fphar.2022.917162.